AUS
NZ
UK
CA
USA
IND
Headlines
- Ballentine Partners LLC Expands Medtronic Stake
- Notable Institutional Investors Boost Holdings in MDT
- Medtronic Sees Growth Amidst Increased Investment
Medtronic Sees Surge in Institutional Investment
Medtronic plc (NYSE:MDT) has witnessed an impressive rise in investor interest, particularly from institutional players, who are significantly increasing their positions in the medical technology sector giant. The latest filing with the Securities and Exchange Commission reveals that Ballentine Partners LLC, a well-established investment firm, boosted its holdings in Medtronic by nearly a quarter in the fourth quarter. This growth in Ballentine Partners LLC's investment translates to a notable addition of shares to its portfolio, bringing its total ownership to over 16,000 shares. As of the latest filing, Medtronic's shares held by Ballentine Partners were valued at approximately $1.3 million.
Other institutional investors have also shown increased confidence in Medtronic, as evidenced by similar movements in several key funds. State Street Corp, one of the largest financial entities, raised its stake in Medtronic by a modest percentage, acquiring additional shares during the third quarter. This brings State Street’s total shareholding to an impressive number, further solidifying its confidence in Medtronic’s prospects.
Additionally, Pzena Investment Management LLC made notable strides by boosting its position in the company by over three percent during the same period. This increase means Pzena now owns millions of shares of Medtronic, with the total value of their holdings reaching several hundred million dollars. This significant expansion is indicative of a growing trust in Medtronic’s position in the industry.
One of the most remarkable moves comes from UBS Asset Management, a division of UBS Group, which saw a monumental increase in its investment. UBS AM ramped up its holdings by a staggering 436.7% during the third quarter, acquiring millions of additional shares. This move is particularly notable given the scale of the purchase and reflects strong institutional belief in the long-term performance of Medtronic.
Furthermore, Raymond James & Associates, a prominent investment firm, also grew its Medtronic holdings by over two percent in the third quarter. This consistent interest from multiple institutional investors speaks volumes about the overall sentiment surrounding Medtronic’s stability and future prospects within the medical technology field.
Fisher Asset Management LLC has similarly expanded its stake in Medtronic by over eleven percent. The firm now holds millions of shares in the company, showcasing its faith in Medtronic’s future potential and its growing presence within the sector.
As of now, the vast majority of Medtronic's shares are held by institutional investors, accounting for over 80% of the total outstanding shares. This dominance by institutional players suggests that Medtronic continues to be viewed as a strong contender in the medical technology space. It also reflects a broader trend of confidence in the company’s ability to navigate the evolving healthcare landscape.
